PTAB Rejects Alvogen’s Inter Partes Review Request for Revlimid Patent

Drug Industry Daily
A A
The U.S. Patent Trial and Appeal Board (PTAB) rejected a petition from generic drugmaker Alvogen seeking to invalidate Celgene’s Revlimid patent.

To View This Article:

Login

Subscribe To Drug Industry Daily